ARGX-118 was designed as a highly differentiated antibody against Galectin-10, the protein of Charcot-Leyden crystals (CLCs), which are implicated as a major contributor to airway inflammation and to the persistence of mucus plugs.
ARGX-118 was built in collaboration with Prof. Bart Lambrecht, M.D., Ph.D. who identified the first novel airway inflammation target in decades.
For more info on this Case Study, click the link below.
ARGX-118 is designed to bind to an epitope of Galectin-10 that is critical for crystal packing. It not only prevents Galectin-10 crystallization, but also rapidly solubilizes Charcot-Leyden crystals (CLCs).
CLCs are frequently observed in the mucus of patients with eosinophilic respiratory diseases and promote type 2 immunity and mucus plugging. By nebulization of ARGX-118, argenx aims to improve the viscoelasticity of mucus.